African swine fever virus IAP-like protein induces the activation of nuclear factor kappa B by Rodríguez, Clara I. et al.
JOURNAL OF VIROLOGY, Apr. 2002, p. 3936–3942 Vol. 76, No. 8
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.8.3936–3942.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
African Swine Fever Virus IAP-Like Protein Induces the Activation of
Nuclear Factor Kappa B
Clara I. Rodrı´guez, Marı´a L. Nogal, Angel L. Carrascosa, Marı´a L. Salas, Manuel Fresno,
and Yolanda Revilla*
Centro de Biologı´a Molecular “Severo Ochoa,” Universidad Autónoma, Cantoblanco, 28049 Madrid, Spain
Received 23 October 2001/Accepted 10 January 2002
African swine fever virus (ASFV) encodes a homologue of the inhibitor of apoptosis (IAP) that promotes cell
survival by controlling the activity of caspase-3. Here we show that ASFV IAP is also able to activate the
transcription factor NF-B. Thus, transient transfection of the viral IAP increases the activity of an NF-B
reporter gene in a dose-responsive manner in Jurkat cells. Similarly, stably transfected cells expressing ASFV
IAP have elevated basal levels of c-rel, an NF-B-dependent gene. NF-B complexes in the nucleus were
increased in A224L-expressing cells compared with control cells upon stimulation with phorbol myristate
acetate (PMA) plus ionomycin. This resulted in greater NF-B-dependent promoter activity in ASFV IAP-
expressing than in control cells, both in basal conditions and after PMA plus ionophore stimulation. The
elevated NF-B activity seems to be the consequence of higher IB kinase (IKK) basal activity in these cells.
The NF-B-inducing activity of ASFV IAP was abrogated by an IKK-2 dominant negative mutant and enhanced
by expression of tumor necrosis factor receptor-associated factor 2.
The NF-B transcription factors are a ubiquitously ex-
pressed family of proteins involved in the regulation of many
immune and inflammatory functions. NF-B is composed of
homo- or heterodimers of Rel family members (3, 10). In most
cells, NF-B factors are present in an inactive form in the
cytoplasm of resting cells, retained through complex formation
with a family of inhibitors, the IB proteins (IB, IB, and
IBε) (3, 10).
NF-B activation results from the phosphorylation of two
conserved serines at the N terminus that renders IB suscep-
tible to proteolysis via the ubiquitin proteosome pathway (31,
40). After the degradation of IB, NF-B can translocate to
the nucleus to activate gene expression. The signal-induced
phosphorylation of IB is accomplished by an IB kinase
(IKK) complex that contains two kinases, IKK-1 and IKK-2, as
well as several scaffolding proteins (19, 42). The IKKs are
activated by signals derived from the tumor necrosis factor
receptor (TNF-R), which may involve other kinases, such as
NIK (18), MEKK-1, -2, and -3 (17), and PK-C (30).
TNF is a pleiotropic cytokine inducing a variety of biologic
responses (for a review, see reference 38). Binding of TNF to
its receptors TNF-R1 and TNF-R2 generates two types of
signals, one that initiates programmed cell death and another
that leads to activation of the transcription factor NF-B (1).
TNF-induced cell death is mediated primarily by TNF-R1 due
to the presence of an 80-amino-acid region known as the death
domain, which is absent in TNF-R2 (32, 35), whereas TNF-R2
is mostly involved in cell activation, cell survival, and antiapop-
totic functions (34). Both TNF-R1 and TNF-R2 can stimulate
NF-B activation (9, 15, 16, 36). It is generally accepted that
the overall outcome of death versus survival depends on the
balance of NF-B and apoptotic signals.
Thus, activation of NF-B can inhibit apoptotic cell death
(2) and appears to play a protective role in TNF-mediated
apoptosis by activating the transcription of several antiapop-
totic genes, including the inhibitor of apoptosis (IAP) (12),
A20 (14), and Bcl-X and Bcl-2 (5, 33, 43).
Cellular proteins of the family of baculovirus IAPs, including
several human IAP relatives, have been shown to interfere with
apoptotic processes (8). Part of this ability is mediated by their
direct inhibition of caspase activity, but they can also mediate
their antiapoptotic activity by their ability to activate NF-B
(6). c-IAP1 and c-IAP2 specifically inhibit the active forms of
caspase-3 and caspase-7 and also block the etoposide-induced
processing of caspase-3. c-IAP2, whose expression is activated
by NF-B, cannot prevent TNF-mediated apoptosis in cells in
which NF-B is inhibited (6). It is also known that v-Rel, the
viral homologue of the NF-B family member c-Rel, induces
expression of an avian form of IAP (41). Furthermore, c-IAP1
and c-IAP2 can associate with TNF-R2, although they cannot
bind it directly. They are recruited to the receptor by binding
to TNF receptor-associated factor 1 (TRAF-1) and TRAF-2
heterocomplexes, being therefore involved in NF-B activation
by TNF (27).
African swine fever virus (ASFV) is a large DNA virus that
infects different species of suids, causing an acute and fre-
quently fatal disease (37). Infection by ASFV is characterized
by the absence of a neutralizing immune response, which has
prevented the development of a conventional vaccine. The
analysis of the complete 170-kb DNA sequence of this virus
has revealed several genes capable of modulating host re-
sponse (39). Among these, A224L encodes a 27-kDa protein
homologous to IAP members (4) which inhibits caspase-3 ac-
tivation both in IAP-transfected cells and during viral infection
by interaction with the catalytic fragment of caspase-3 (20).
Using stably or transiently transfected cells, we show here that
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ASFV IAP (A224L) is also able to activate NF-B, its effect
being dependent on IKK activity.
This is the first description of a viral IAP-like gene that is
able to activate NF-B that not only helps explain the ability of
ASFV to modulate the immune response by regulating NF-B
activation either positively or negatively (23, 24) but also helps
clarify the molecular mechanisms of NF-B activation.
MATERIALS AND METHODS
Cells and reagents. Jurkat cells were obtained from the American Type Cul-
ture Collection and grown in RPMI 1640 medium (Gibco, Rockville, Md.),
supplemented with 5% heat-inactivated fetal bovine serum (FBS; Gibco, Rock-
ville, Md.) and containing 2 mM L-glutamine plus 100 g of streptomycin and 100
U of penicillin per ml and nonessential amino acids, at 37°C in a 7% CO2 in air
saturated with a water vapor incubator.
Recombinant TNF- was purchased from Genzyme (Cambridge, Mass.).
Phorbol myristate acetate (PMA) and calcium ionophore A23187 were pur-
chased from Sigma (St. Louis, Mo.).
Antisera from rabbits hyperimmunized with peptides derived from human
c-Rel (antibody 265), anti-p65 antibody, and NF-B essential modulator
(NEMO) antibody 3328 were kindly provided by Nancy Rice (National Cancer
Institute Cancer Research and Development Center [NCI-FCRDC], Frederick,
Md.).
Plasmids. The pNF3TK Luc reporter plasmid contains a 3 tandem repeat of
the NF-B-binding motif of the H-2k gene upstream of the thymidine kinase
minimal promoter and the luciferase reporter gene The AP-1-Luc plasmid in-
cludes the AP-1-responsive (73 to 63 bp) region of the human collagenase
promoter fused to the luciferase gene.
Expression plasmids encoding either wild-type or a dominant negative mutant
of IKK-2 were kindly provided by J. Moscat (Centro de Biologı´a Molecular
Severo Ochoa, Madrid, Spain), and the TRAF-2 expression vector plasmid was
kindly provided by B. Seed (21). pcDNA-IAP was generated by cloning the
A224L open reading frame into the pcDNA3 mammalian expression vector
(Invitrogen).
Transfections. Jurkat T cells were transfected with 1 g of specific plasmid per
106 cells using the Lipofectamine Plus reagent (Invitrogen) according to the
manufacturer’s instructions. Twenty-four hours after transfection, the cells were
treated or not with TNF- (10 ng/ml) or PMA (10 ng/ml) plus calcium ionophore
(1 M) for 6 h. They were then lysed with passive cell culture lysis reagent
(Promega, Madison, Wis.) and microcentrifuged at full speed for 5 min at 4°C,
and 20 l of each supernatant was used to determine firefly luciferase activity in
a Monolight 2010 luminometer (Analytical Luminiscence Laboratory). Results
were expressed as the fold increase in luminescence relative to the value ob-
tained with the nonstimulated control after normalization of protein concentra-
tion, determined by the bicinchoninic acid (BCA) spectrophotometric method
(Pierce, London, United Kingdom). For normalization of transfection efficiency,
cells were cotransfected with 100 ng of the reporter plasmid pTK-Renilla (Pro-
mega, Madison, Wis.), and luciferase activity was recorded using the dual lucif-
erase assay (Promega, Madison, Wis.). Results are always expressed as values
normalized to Renilla activity.
For G418 selection, cells were transfected with 0.5 g of pcDNA3 or pcDNA3-
A224L as described above. Two days later, antibiotic selection was applied (1 mg
of G418 [Sigma] per ml). Cells were refed with fresh medium every 3 days until
colonies were apparent (2 to 3 weeks).
RT-PCR analysis of A224L mRNA expression. Total RNA was isolated by
using the Trizol reagent (Gibco) following the manufacturer’s recommendations.
First-strand cDNA was obtained from 1 g of total RNA (previously denatured
by heating for 2 min at 65°C and placed on ice) with 10 l of reverse transcriptase
reaction mixture containing 10 Moloney murine leukemia virus reverse tran-
scription (RT) buffer (Epicentre), 10 mM dithiothreitol, 0.5 mM oligo(dT), a 50
M concentration of each of the four deoxyribonucleoside triphosphates, 12.5 U
of Moloney murine leukemia virus reverse transcriptase, and 20 U of RNasin
(Promega). The reaction mixtures, in a final volume of 50 l with RNase-free
water, were incubated for 1 h at 37°C. For PCR, a variable amount of the cDNA
obtained (5 l) was used in a total volume of 50 l of a PCR mixture. PCR
amplification was carried out with 30 cycles of denaturation at 94°C for 1 min,
annealing at 55°C for 90 s, and extension at 72°C for 2 min. PCR products were
electrophoresed on 1% agarose gels containing ethidium bromide.
Western blot analysis. Cells were washed twice with phosphate-buffered saline
(PBS) and lysed in TNT buffer (20 mM Tris-HCl [pH 7.6], 200 mM NaCl, 1%
Triton X-100) supplemented with protease inhibitor cocktail tablets (Roche).
Protein concentration was determined by the BCA method. Cell lysates (50 g
of protein) were separated in a sodium dodecyl sulfate (SDS)–10% polyacryl-
amide gel, blotted onto an Immobilon extra membrane (Amersham), and re-
acted with specific primary antibodies. Membranes were exposed to horseradish
peroxidase-conjugated secondary antibodies (Dako), followed by chemilumines-
cence (ECL; Amersham) detection by autoradiography.
Solid-phase in vitro phosphorylation kinase assay. The fusion proteins gluta-
thione S-transferase (GST)-	B-(1–70) and mutant S32A-S36A-GST-IB-(1–
70) were expressed from plasmids kindly provided by Nancy Rice (NCI-FCRDC,
Frederick, Md.).
We used 0.5 g of GST-IB- or mutant GST-IB- as the substrate for in
vitro phosphorylation in which whole-cell extracts from stimulated pcDNA and
pcDNA A224L Jurkat cells were assayed. Each 25 l of whole-cell extract was
made from 106 Jurkat cells, stimulated with 20 ng of PMA plus 1 g of ionomycin
for 15 min. After stimulation, cells were washed in PBS and lysed in TNT buffer
supplemented with phosphatase inhibitors (1 mM NaVO3, 10 mM NaF, and 10
mM Na2MoO4) and protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride,
1 g of pepstatin, 2 g of leupeptin, and 2 g of aprotinin per ml).
Cleared extracts were incubated for 12 h with 1 l of specific NEMO anti-
serum to immunoprecipitate IKKs. Immunoprecipitates were finally resus-
pended in kinase buffer containing 20 mM HEPES (pH 7.6), 20 mM MgCl2, 20
mM -glycerophosphate, 20 M ATP, and 1 Ci of [32P]ATP (specific activity,
3,000 Ci/mol) supplemented with phosphatase inhibitors and mixed with the
recombinant GST-IB- or recombinant mutated GST-IB- immobilized on
Sepharose beads. After 20 min at 30°C, the kinase reaction was terminated by
washing with TNT buffer. Phosphorylated proteins were separated in an SDS–
10% PAGE gel, dried and developed by autoradiography.
Electrophoretic mobility shift assay. Nuclear extracts from Jurkat cells were
prepared as previously described (22). Briefly, cells were collected by centrifu-
gation, washed twice with PBS, and resuspended in 400 l of ice-cold buffer A
(10 mM HEPES [pH 7.6], 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.75 mM
spermidine, 0.15 mM spermine, 1 mM dithiothreitol, 0.5 mM phenylmethylsul-
fonyl fluoride, 10 mM Na2MoO4, 1 g of pepstatin, 2 g of leupeptin, and 2 g
of aprotinin per ml). After 15 min on ice, Nonidet P-40 was added to reach a final
concentration of 5% (wt/vol), and cells were vortexed and centrifuged for 30 s at
15,000  g. The nuclear pellet was extracted with 50 l of buffer C (20 mM
HEPES [pH 7.6], 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol,
0.5 mM phenylmethylsulfonyl fluoride, 10 mM Na2MoO4, 1 g of pepstatin, 4 g
of leupeptin, and 4 g of aprotinin per ml) for 30 min on a rocking platform and
further centrifuged at 15,000  g for 10 min. Protein concentrations were de-
termined by BCA assay.
The DNA-binding assays were performed essentially as reported previously
(24) using as the labeled probe the double-stranded B element of the interleu-
kin-2 receptor alpha promoter (5
-GCAGGGGAATCTCCCTCT-3
). For anti-
body-specific supershifts, 1 l of anti-p65 antibody, kindly provided by Nancy
Rice (NCI-FCRDC, Frederick, Md.), was incubated with the nuclear extract for
20 min on ice before incubation with the radioactive probe. Bound complexes
were separated in a 5% acrylamide gel, and their specificity was determined by
competition with a 50-fold molar excess of the same unlabeled oligonucleotide.
RESULTS
ASFV IAP (A224L) activates NF-B. Some cellular IAPs
have been shown to activate NF-B. Therefore, we tested the
effect of the ASFV IAP-like molecule in NF-B activation by
transiently transfecting the gene (A224L) into Jurkat cells to-
gether with an NF-B reporter gene. As shown in Fig. 1,
ectopic expression of A224L was able to activate the reporter
activity in a dose-responsive manner.
To better understand the mechanism by which A224L was
activating NF-B, we generated Jurkat cell lines that stably
express the ASFV A224L gene after selection with G418 (Fig.
2). As control cells, we used pooled populations of clones
stably expressing the empty plasmid (pcDNA3). In agreement
with the transient transfection assays, pooled populations of
Jurkat clones stably expressing the A224L gene have greater
basal luciferase activity (about twofold) than the control
pcDNA3-transfected cells, after transfection with an NF-B-
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luciferase reporter gene (Fig. 3A, left panel). Interestingly,
those cells also responded better to potent stimuli of NF-B
activation, such as PMA plus ionophore or TNF- (data not
shown), than the control cells. This effect was specific, since
A224L had no effect on basal or PMA plus ionophore AP-1-
dependent transcription (Fig. 3A, right panel).
Next, we assayed whether this elevated NF-B activation
was associated with a higher level of active NF-B in the
nucleus of cells stably expressing the viral IAP. As shown in
Fig. 3B, unstimulated cells showed almost undetectable nu-
clear complexes bound to NF-B oligonucleotides, as detected
by electrophoretic mobility shift assays. A224L-expressing cells
have barely detectable active NF-B complexes. Interestingly,
upon stimulation with PMA plus ionophore, more active
NF-B nuclear complexes were detected in A224L cells than in
control pcDNA3-transfected cells. Those complexes represent
active NF-B, as demonstrated by supershifting by p65-specific
antibodies (Fig. 3B).
Extracts of ASFV IAP-expressing cells also showed higher
levels of NF-B, as detected by Western blot (Fig. 3C) using a
specific anti-c-Rel antibody, further confirming that NF-B is
up regulated in A224L-expressing cells and indicating that, as
expected, the enhancement of NF-B activity found in A224L-
expressing cells stimulates the synthesis of c-Rel, since c-rel is
a B-dependent gene.
ASFV IAP activity depends on IKK activity. NF-B activity
is the result of I- phosphorylation by IKKs and posterior
degradation. Thus, to investigate the mechanism of NF-B
activation mediated by the viral IAP, we tested whether IKKs
were activated in A224L-expressing cells. For this, cell extracts
from both pcDNA- and A224L-expressing cells were prepared
and immunoprecipitated with anti-IKK-specific antiserum
(NEMO). In parallel, and as a control, an irrelevant anti-c-Rel
antiserum was also used to immunoprecipitate extracts from
A224L-expressing cells (Fig. 4A). The immunoprecipitates
were assayed for in vitro IKK activity using both recombinant
GST-I- and mutant GST-I- (which lacks serine resi-
dues Ser-32 and Ser-36 and consequently cannot be phosphor-
ylated) as substrates, as described in Materials and Methods.
A higher amount of phosphorylated GST-IB- was ob-
tained in A224L-transfected cells (Fig. 4B), and, as expected,
no phosphorylation was observed with the immunoprecipitate
obtained with the anti-c-Rel antibody (not shown) or when
mutated GST-I- was used as the substrate (Fig. 4C). In
FIG. 1. A224L increases NF-B-driven transcription. Jurkat T lym-
phocytes were transfected with the control vector pcDNA3 or graded
doses of pCMV-A224L plasmid, together with the luciferase NF-B
reporter construct. After 14 h, luciferase activity was measured in cell
extracts. Shown are the means  standard error (SE) of relative light
unit (RLU) values per 0.1 g of protein from transfected cells, ob-
tained from three independent experiments.
FIG. 2. Transcription of ASFV IAP gene in Jurkat cells stably transfected with A224L. RNAs were isolated from a pool of three different clones
of A224L-transfected (lane 2) or pcDNA-transfected (lane 3) Jurkat cells. PCR products were generated using A224L-specific primers, and cDNAs
were synthesized from RNAs and resolved in a 1.5% agarose gel. A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control was used to
control the RNA content and integrity. Positions of molecular size markers are included, and the sizes (in kilobase pairs) are indicated on the left.
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agreement with the above results, we conclude that A224L-
expressing cells have higher (about twofold) IKK activity in
both unstimulated (not shown) and PMA-stimulated cells.
To further confirm the role of IKK in A224L activity, we
transiently transfected A224L-expressing cells with an IKK
(	KK2) plasmid or the pRK5 empty plasmid. As expected, the
transfection of active IKK was able to activate the NF-B
reporter gene in pcDNA cells (Fig. 5). Furthermore, and more
FIG. 3. Cells stably expressing A224L have elevated NF-B activity. (A) Stimulation of NF-B-directed transcription. Jurkat cells stably
expressing A224L (shaded bars) or pcDNA as a control (open bars) were cotransfected with NF-B (left panel) or AP-1 (right panel) luciferase
reporter constructs. After 12 h of growth, the indicated cultures were exposed to PMA plus ionophore (Io) or left unstimulated. Whole-cell extracts
were prepared at 24 h posttransfection and assayed for luciferase activity. Relative light units (RLU) per 0.1 g of protein from triplicate
transfections (mean  SE) are shown. (B) A224L expression enhances NF-B activity in the nucleus of stimulated cells. Supershift electrophoretic
mobility shift assays for NF-B DNA-binding activity were performed with nuclear extracts collected from cells not expressing or expressing A224L
stimulated with PMA plus ionophore. The observed shift in mobility with specific anti-p65 antibody is indicated by an arrowhead. (C) Whole-cell
extracts (50 g) from Jurkat cells stably transfected with pcDNA or pcDNA-A224L were prepared, subjected to SDS-PAGE, and detected by
immunoblotting with c-Rel-specific antibody. A representative experiment from three different assays is shown. A control using an antiactin
antibody is also included to rule out differences in loading or transference. The increased amount of c-Rel in A224L-expressing cells was monitored
by densitometry and is shown as optical density (O.D.).
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interestingly, in cells stably expressing A224L, the synergism in
NF-B reporter activation between IKK and A224L was ev-
ident. It is also important to note that transfection of IKK
eliminated the ability of TNF- to activate the reporter gene,
indicating that IKK’s activity is an event downstream of the
TNF- action.
To test the specificity of this effect, we transfected a kinase-
dead dominant negative mutant of IKK into cells stably ex-
pressing A224L, which abrogated the enhanced activation of
NF-B reporter activity.
A224L cooperates with TRAF-2 in activation of NF-B. Cel-
lular IAP2 seems to act upstream of NF-B in the TNF sig-
naling cascade at a step leading to IB- degradation (36).
Previous biochemical studies have suggested that the induction
of NF-B by TNF is mediated via TRAF-2 (27). Although
recent evidence indicates that c-IAP2 interacts with TRAF-2
and this has been proposed as a mechanism by which c-IAP2
activates NF-B (6), the precise role of c-IAP2 in this cytokine-
signaling pathway remains unclear.
In order to investigate the mechanism operating in the viral
IAP in relation to TRAF-2, we transiently transfected TRAF-2
and A224L genes into Jurkat cells, either separately or com-
bined. As shown in Fig. 6, ectopic expression of the plasmid
containing A224L induced the activation of NF-B in Jurkat
cells, as expected. The transfection of a plasmid containing
TRAF-2 slightly enhanced the NF-B activity. Interestingly,
higher activation was obtained when we cotransfected cells
with plasmids expressing A224L and TRAF-2, representing
more than an additive effect on NF-B activation. This last
result suggests that A224L could activate IKKs by a mechanism
involving the TRAF-2 molecule.
DISCUSSION
Here we describe for the first time a viral IAP-like molecule
that is able to activate NF-B. Similar results have been de-
scribed previously for cellular XIAP, c-IAP1, and c-IAP2 (7),
defining a new positive regulatory survival mechanism for
IAPs, although the specific pathways involved are not fully
understood. It was recently reported that the expression of
XIAP in endothelial cells leads to increased nuclear translo-
cation of the p65 subunit of NF-B through a novel signaling
pathway that involves the mitogen-activated protein kinase
kinase kinase (MAP3K) TAK1 (11).
The viral IAP A224L was classified as an IAP homologue
based on the existence of a single baculovirus internal repeat
(BIR) motif, which defines the members of the IAP family.
However, A224L does not have a canonical ring motif, which is
present in many, although not in all, members of the IAP
family and to which the ability to activate NF-B has been
mapped (6). A224L contains a sequence that may constitute a
zinc finger domain of the four-cysteine type at the C-terminal
region. In contrast to this, the zinc finger sequences in bacu-
lovirus IAPs and in cellular IAP genes shown to activate
NF-B are ring fingers of the C3HC4 type (7). Thus, it was
somewhat surprising that, lacking this domain, A224L was able
FIG. 4. Activation of IKKs by A224L. (A) Cleared extracts from
106 pcDNA-A224L stably transfected Jurkat cells were incubated and
immunoprecipitated with 1 l of NEMO antiserum or with anti-c-Rel
antibody as a control. Immunoprecipitates were separated by SDS-
PAGE and revealed with a monoclonal antibody against IKKs. (B and
C) Cleared extracts from pcDNA- and A224L-transfected cells were
immunoprecipitated with 1 l of NEMO antiserum and used in an in
vitro kinase assay as described in Materials and Methods, using (B) 0.5
g of GST(1–115)-IB- or (C) 0.5 g of mutated IB- as the
substrate. Proteins were separated by SDS–10% PAGE and developed
by autoradiography. Data were reproducible for at least three separate
kinase assays performed under the same conditions.
FIG. 5. Involvement of IKKs in ASFV IAP-mediated NF-B activ-
ity. pcDNA3-transfected or A224L stably expressing Jurkat cells were
cotransfected with 1 g of the NF-B-dependent promoter-luciferase
reporter gene together with 1 g of pRK5 empty plasmid or pRK5
IKK. After 24 h of culture, cells were either untreated or stimulated
with TNF- (50 ng/ml) for 16 h. The specificity of the effect was
ensured by transfection of 1 g of a dominant negative mutant of the
IKK expression vector in pcDNA3-expressing cells or A224L-ex-
pressing cells. Relative luciferase values (RLU) per microgram are
averages (mean  SE) of two representative experiments in which
each transfection was done in triplicate.
FIG. 6. ASFV IAP cooperates with TRAF-2 in increasing NF-B
activity. A total of 106 Jurkat T lymphocytes were transiently cotrans-
fected with 1 g of NF-B luciferase reporter and 500 ng of pcDNA
and pcDNA-A224L or 50 ng of the expression vector for TRAF-2.
Values represent the fold induction of reporter gene activity for the
respective transfections, which were done in triplicate. The value for
pcDNA-transfected cells was 830 RLU and was considered 100%
activity (onefold).
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to activate NF-B, and this result could indicate that this do-
main is dispensable for NF-B activation by some IAPs.
Given the homology in the BIR sequence and the functional
relationship between ASFV IAP and cellular IAPs in terms of
inhibition of caspases (20), it is possible that the viral gene
derives from a cellular gene. Genes that modulate apoptosis
might be incorporated into viral genomes to sustain host cell
viability (13). Gene products of several viruses control apopto-
sis by interacting with components of the conserved pathways
that regulate cell death. Our results show that ASFV IAP is
able to activate NF-B, and therefore the ability to activate this
transcriptional factor is not restricted to IAPs of cellular origin.
Moreover, suppression of TNF-mediated cell death, which
mainly involves inactivation of caspase-8 by c-IAP1 and c-
IAP2, is thought to be mostly mediated by the ability of those
IAPs to interact with TNF receptor proteins such as TRAF-2,
resulting in NF-B activation (6, 26). Although we were not
able to demonstrate interaction of A224L with TRAF-2 in
immunoprecipitation assays, the viral protein seems to be sim-
ilar to c-IAP1 and c-IAP2, since it is able to functionally co-
operate with TNF-R-associated protein TRAF-2 and to en-
hance NF-B activation even in the absence of stimulus.
The involvement of IKKs in A224L-mediated NF-B acti-
vation is supported by the fact that in A224L-transfected cells
a constitutive activation of 	KK was observed. In addition, the
effect of A224L could be inhibited by a kinase-dead dominant
negative mutant of 	KK. In this regard, it is interesting that
A224L is similar to XIAP (11). Therefore, our results indicate
that A224L is able to directly activate NF-B by inducing IKK
activity. This is the first demonstration that any viral IAP in-
duces IKK activity. Moreover, the activation of NF-B was
further enhanced when the cells were stimulated with TNF or
PMA plus ionophore. This latter result is interesting because
PMA plus ionophore activation does not activate TRAF as
TNF does. This can be taken as an indication that A224L was
able to activate NF-B in a TNF-R-independent manner. Since
A224L was able to activate NF-B in the presence of PMA or
TNF, this suggests that A224L should act downstream of
where the PMA and TNF signals converge. In support of this
is the fact that we were unable to coimmunoprecipitate A224L
and TRAF-2, which suggests a possible role for A224L in both
pathways.
c-IAP1 and c-IAP2 have been shown to physically interact
with TNF-R via TRAF-1 and TRAF-2 association. The amino-
terminal BIR-containing region of these IAPs is required for
the interaction with TRAFs. The interaction of c-IAP1 and
c-IAP2 with TRAF-1 and TRAF-2 appears to be specific in
that these IAPs do not bind to TRAF-3, TRAF-4, TRAF-5, or
TRAF-6, and other IAPs (XIAP and NIAP) reportedly fail to
bind TRAFs altogether (28). Thus, TRAF binding is not a
universal feature of IAP family proteins. In this regard, A224L
is similar to XIAP, since we could not demonstrate an inter-
action of the viral protein with TRAF-2. However, XIAP may
act by binding to some upstream kinases involved in IKK
activation. Thus, it is tempting to speculate that A224L may
behave like XIAP.
In addition to the effect on NF-B, a study has provided
evidence that some IAP family proteins can regulate the Jun
amino-terminal kinase (JNK) pathway (29). Specifically, JNK1
activation induced by overexpression of pro-caspase-1 is re-
portedly augmented by coexpression of XIAP. However, we
have not detected any effect on either basal or stimulated AP-1
activation in cells stably or transiently transfected with ASFV
IAP.
Here we present evidence of a new type of strategy to evade
host response, not described previously for mammalian vi-
ruses: the existence of a viral IAP that not only blocks
caspase-3 activation (20) but also activates NF-B. It is inter-
esting that the virus encodes an IB-like molecule (A238L)
that behaves as a bona fide IB inhibitor (24). However,
A238L and A224L are expressed at different times during
ASFV infection, A238L being an early protein and A224L a
late protein in the viral cycle. As A224L induces, whereas
A238L blocks, NF-B activation, this may suggest that the
virus requires a low NF-B activity at early times of the viral
cycle to avoid immune responses but a high activity at late
times, probably to prevent apoptosis. The virus also encodes
another apoptosis inhibitor, a Bcl-2-like molecule (25), which
is an early protein in the viral cycle that could also act to inhibit
programmed cell death at early times after infection.
Taken together, these results indicate that the control of
apoptosis and survival in the host cell infected by ASFV is a
tightly regulated process which must be of crucial importance
both for replication of the virus and for viral evasion of the
immune response.
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